Analytic Extractor suits bioanalytical sample preparation.
Share:
Press Release Summary:
EVOLUTE ABN (Acidic Basic Neutral) provides means to extract drugs from biological fluids through solid phase extraction (SPE). Able to process plasma extracts and quantify drug concentrations using LC-MS/MS analysis, product reduces problems of ion suppression and matrix effects. EVOLUTE ABN SPE columns and 96-well plates use polymer-based sorbent to facilitate separation of unneeded matrix materials from analytes.
Original Press Release:
Argonaut Technologies Introduces EVOLUTE(TM) ABN for Bioanalytical Sample Preparation
REDWOOD CITY, Calif., Nov. 9 -- Argonaut Technologies (NASDAQ:AGNT) , a leading provider of chemistry instruments and consumables to help the pharmaceutical industry accelerate drug development, announced the introduction of EVOLUTE ABN (Acidic Basic Neutral), a product to extract drugs from biological fluids through improved solid phase extraction (SPE). EVOLUTE ABN is the first product to be released in the new EVOLUTE family. It is strategically targeted at solving the high throughput sample preparation problems facing bioanalytical laboratories performing drug metabolism, ADME, pharmacokinetic and toxicology studies.
EVOLUTE ABN reduces the problems of ion suppression and matrix effects common with competitive polymer-based SPE products. Using EVOLUTE ABN our customers can now process plasma extracts and more accurately quantify drug concentrations using LC-MS/MS analysis.
"Our initial customers are really excited about the results they are obtaining with EVOLUTE ABN, said Jeff Labadie, senior vice president at Argonaut Technologies. They finally have a superior performing, easy-to-use alternative to what has been a captive market for one of our competitors. We are very pleased at the initial response of the EVOLUTE product family and look forward to establishing another major brand in the Argonaut consumables business."
EVOLUTE ABN SPE columns and 96-well plates use a superior polymer-based sorbent to improve the separation of unneeded matrix materials from the analytes. As a result, extracts are cleaner and allow more accurate quantification of drug candidates and their metabolites. Using EVOLUTE ABN, compounds can be detected by LC-MS/MS technology at lower levels, providing more accurate determination of the concentrations present in the body. Also, EVOLUTE ABN allows chemists to use a generic methodology to minimize sample preparation method development time.
About Argonaut Technologies
Argonaut Technologies, Inc. is a leading provider of consumables, instruments, and services designed to help the pharmaceutical industry accelerate drug development. The company's products enable chemists to increase productivity, reduce operating costs, achieve faster time to market, and test the increasing number of targets and chemical compounds available for drug development. Argonaut Technologies develops products in close consultation and collaboration with scientists from leading pharmaceutical companies. More than 1,200 customers use Argonaut's products worldwide. For more information, visit www.argotech.com or contact Argonaut Technologies at 650-716-1600.
CONTACT: Steve Nelson, Vice President, Business Development of Argonaut Technologies, +1-650-716-1600, or snelson@argotech.com
Web site: www.argotech.com/
